For Eniola Olutogun, the strongest angle is to position the venture as a pharma supply chain and community diagnostics solution, leveraging her pharmacist background and ML expertise to address drug resistance in infectious diseases prevalent in Nigeria (e.g., TB, malaria, AMR). The venture's ability to predict drug resistance from protein sequence alone, without needing crystal structures, is a unique, scalable tool that can be deployed in low-resource settings, aligning perfectly with the program's focus on affordable, tech-driven solutions for low-income populations. Emphasize the regulatory advantage: as a licensed pharmacist, Eniola has insider knowledge of NAFDAC compliance, which is a key program focus.

The applicant is pre-incorporation and pre-revenue, which may be early for some incubators, but the program explicitly targets 'Idea to Prototype' phase, so this is acceptable. The venture's focus on drug resistance prediction is more biotech/pharma AI than typical healthtech (e.g., digital health apps), so the application must clearly articulate the direct healthcare impact in Nigeria, not just global pharma relevance. Also, the program is Nigeria-focused, so the applicant must demonstrate a clear Nigeria-first strategy, despite the venture's global potential.